<pages>
<page id="1" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="121.510,373.477,753.520,512.587" size="44.048">Clinical Performance of HBIg in  
Preventing Recurrent HBV After  
Liver Transplantation <textline bbox="126.550,468.547,748.483,512.587" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="44.040" colourspace="Pattern">Clinical Performance of HBIg in  </textline>
<textline bbox="121.510,421.022,753.520,465.086" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="44.064" colourspace="Pattern">Preventing Recurrent HBV After  </textline>
<textline bbox="224.590,373.477,639.491,417.517" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="44.040" colourspace="Pattern">Liver Transplantation </textline>
</textbox>
<textbox id="1" bbox="189.910,49.192,674.335,192.581" size="21.628799999999995">David K. Imagawa, MD, PhD 
Professor of Clinical Surgery 
Department of Hepatobiliary and Pancreas Surgery 
University of California, Irvine Medical Center 
July 2006 <textline bbox="255.820,164.621,608.004,192.581" font="TimesNewRomanPS-BoldMT" ncolour="1" size="27.960" colourspace="Pattern">David K. Imagawa, MD, PhD </textline>
<textline bbox="294.460,135.612,570.010,155.652" font="Arial-BoldMT" ncolour="1" size="20.040" colourspace="Pattern">Professor of Clinical Surgery </textline>
<textline bbox="189.910,106.807,674.335,126.871" font="Arial-BoldMT" ncolour="1" size="20.064" colourspace="Pattern">Department of Hepatobiliary and Pancreas Surgery </textline>
<textline bbox="216.670,77.992,647.229,98.032" font="Arial-BoldMT" ncolour="1" size="20.040" colourspace="Pattern">University of California, Irvine Medical Center </textline>
<textline bbox="386.980,49.192,477.000,69.232" font="Arial-BoldMT" ncolour="1" size="20.040" colourspace="Pattern">July 2006 </textline>
</textbox>
</page>
<page id="2" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="296.280,471.301,567.897,521.341" size="50.04">Introduction <textline bbox="296.280,471.301,567.897,521.341" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.040" colourspace="Pattern">Introduction </textline>
</textbox>
<textbox id="1" bbox="142.780,334.208,743.780,422.668" size="27.968">Orthotopic liver transplantation (OLT) remains  
the primary curative modality for end-stage liver  
disease from chronic hepatitis B (HBV) infection  <textline bbox="142.780,394.708,716.939,422.668" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">Orthotopic liver transplantation (OLT) remains  </textline>
<textline bbox="142.780,364.463,741.454,392.447" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">the primary curative modality for end-stage liver  </textline>
<textline bbox="142.780,334.208,743.780,362.168" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">disease from chronic hepatitis B (HBV) infection  </textline>
</textbox>
<textbox id="2" bbox="142.780,162.823,738.190,281.508" size="27.966">Initial attempts at OLT without  
immunoprophylaxis in this patient population  
resulted in over 80% re-infection of the allograft  
followed by accelerated graft failure  <textline bbox="142.780,253.548,518.395,281.508" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">Initial attempts at OLT without  </textline>
<textline bbox="142.780,223.308,702.120,251.268" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">immunoprophylaxis in this patient population  </textline>
<textline bbox="142.780,193.068,738.190,221.028" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">resulted in over 80% re-infection of the allograft  </textline>
<textline bbox="142.780,162.823,591.503,190.807" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">followed by accelerated graft failure  </textline>
</textbox>
<figure name="Image28" bbox="115.780,395.060,142.660,423.020" src="Image28.2x2.bmp" width="26" height="27">
</figure>
<figure name="Image32" bbox="115.780,253.900,142.660,281.860" src="Image32.2x2.bmp" width="26" height="27">
</figure>
</page>
<page id="3" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="296.280,471.301,567.897,521.341" size="50.04">Introduction <textline bbox="296.280,471.301,567.897,521.341" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.040" colourspace="Pattern">Introduction </textline>
</textbox>
<textbox id="1" bbox="142.780,302.098,738.300,420.817" size="27.966">Extra-hepatic reservoirs of HBV, such as  
peripheral blood mononuclear cells and various  
organs, likely contributed to the high rate of re- 
infection  <textline bbox="142.780,392.833,652.495,420.817" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">Extra-hepatic reservoirs of HBV, such as  </textline>
<textline bbox="142.780,362.578,738.300,390.538" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">peripheral blood mononuclear cells and various  </textline>
<textline bbox="142.780,332.338,721.201,360.298" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">organs, likely contributed to the high rate of re- </textline>
<textline bbox="142.780,302.098,254.928,330.058" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">infection  </textline>
</textbox>
<textbox id="2" bbox="142.780,130.688,745.402,249.388" size="27.966">These disappointing results caused many  
centers to abandon transplantation as a  
treatment option for chronic HBV infection in the  
late 1980s  <textline bbox="142.780,221.428,666.163,249.388" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">These disappointing results caused many  </textline>
<textline bbox="142.780,191.183,643.022,219.167" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">centers to abandon transplantation as a  </textline>
<textline bbox="142.780,160.928,745.402,188.888" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">treatment option for chronic HBV infection in the  </textline>
<textline bbox="142.780,130.688,279.868,158.648" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">late 1980s  </textline>
</textbox>
<figure name="Image28" bbox="115.780,393.190,142.660,421.174" src="Image28.0.2x2.bmp" width="26" height="27">
</figure>
<figure name="Image28" bbox="115.780,221.780,142.660,249.740" src="Image28.1.2x2.bmp" width="26" height="27">
</figure>
</page>
<page id="4" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="192.190,481.186,671.653,531.250" size="50.064">HBIg Immunotherapy <textline bbox="192.190,481.186,671.653,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">HBIg Immunotherapy </textline>
</textbox>
<textbox id="1" bbox="163.150,297.968,696.599,416.687" size="27.966">A review of domestic and international  
reports on combination therapy with HBIg  
and a nucleoside analog after OLT reveals  
consistent results <textline bbox="163.150,388.703,642.936,416.687" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">A review of domestic and international  </textline>
<textline bbox="163.150,358.448,684.940,386.408" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">reports on combination therapy with HBIg  </textline>
<textline bbox="163.150,328.208,696.599,356.168" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">and a nucleoside analog after OLT reveals  </textline>
<textline bbox="163.150,297.968,379.588,325.928" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">consistent results </textline>
</textbox>
<textbox id="2" bbox="163.150,187.068,666.791,245.268" size="27.96">Low recurrence rates up to 5 years post- 
transplant <textline bbox="163.150,217.308,666.791,245.268" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">Low recurrence rates up to 5 years post- </textline>
<textline bbox="163.150,187.068,286.258,215.028" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">transplant </textline>
</textbox>
<textbox id="3" bbox="163.150,76.160,653.512,134.358" size="27.96">Data covers all HBV patients, including  
patients with high viral loads <textline bbox="163.150,106.398,653.512,134.358" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">Data covers all HBV patients, including  </textline>
<textline bbox="163.150,76.160,513.601,104.120" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">patients with high viral loads </textline>
</textbox>
<figure name="Image32" bbox="139.010,389.040,165.938,417.024" src="Image32.0.2x2.bmp" width="26" height="27">
</figure>
<figure name="Image32" bbox="139.010,217.660,165.938,245.620" src="Image32.1.2x2.bmp" width="26" height="27">
</figure>
<figure name="Image32" bbox="139.010,106.750,165.938,134.710" src="Image32.2.2x2.bmp" width="26" height="27">
</figure>
</page>
<page id="5" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="82.176,466.843,803.473,545.962" size="38.052">Large Studies and Long-term Follow-up for  
HBIg Combination Therapy <textline bbox="82.176,507.898,803.473,545.962" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="38.064" colourspace="Pattern">Large Studies and Long-term Follow-up for  </textline>
<textline bbox="208.180,466.843,667.703,504.883" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="38.040" colourspace="Pattern">HBIg Combination Therapy </textline>
</textbox>
<textbox id="1" bbox="75.072,425.127,140.822,445.191" size="20.064">Author <textline bbox="75.072,425.127,140.822,445.191" font="Arial-BoldMT" ncolour="1" size="20.064" colourspace="Pattern">Author </textline>
</textbox>
<textbox id="2" bbox="222.190,425.127,305.877,445.191" size="20.064">Location <textline bbox="222.190,425.127,305.877,445.191" font="Arial-BoldMT" ncolour="1" size="20.064" colourspace="Pattern">Location </textline>
</textbox>
<textbox id="3" bbox="528.720,425.127,623.439,445.191" size="20.064">Follow-up <textline bbox="528.720,425.127,623.439,445.191" font="Arial-BoldMT" ncolour="1" size="20.064" colourspace="Pattern">Follow-up </textline>
</textbox>
<textbox id="4" bbox="698.300,425.127,819.848,445.191" size="20.064">Recurrences <textline bbox="698.300,425.127,819.848,445.191" font="Arial-BoldMT" ncolour="1" size="20.064" colourspace="Pattern">Recurrences </textline>
</textbox>
<textbox id="5" bbox="31.200,334.792,142.462,383.632" size="20.04">Roche 2003 
Aribizu 2003 <textline bbox="31.200,363.592,139.075,383.632" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Roche 2003 </textline>
<textline bbox="31.200,334.792,142.462,354.832" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Aribizu 2003 </textline>
</textbox>
<textbox id="6" bbox="199.220,334.792,261.645,383.632" size="20.04">France 
Spain <textline bbox="199.220,363.592,261.645,383.632" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">France </textline>
<textline bbox="199.220,334.792,250.462,354.832" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Spain </textline>
</textbox>
<textbox id="7" bbox="31.200,284.392,156.811,304.432" size="20.04">Honaker 2002 <textline bbox="31.200,284.392,156.811,304.432" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Honaker 2002 </textline>
</textbox>
<textbox id="8" bbox="31.200,176.372,168.975,254.012" size="20.04">Dumortier 2003 
Marzano 2001 
Engler 2002 <textline bbox="31.200,233.972,168.975,254.012" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Dumortier 2003 </textline>
<textline bbox="31.200,205.172,159.035,225.212" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Marzano 2001 </textline>
<textline bbox="31.200,176.372,139.135,196.412" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Engler 2002 </textline>
</textbox>
<textbox id="9" bbox="199.220,176.372,325.252,304.432" size="20.0448">Univ. of Tenn,  
USA  
France 
Italy 
Germany <textline bbox="199.220,284.392,325.252,304.432" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Univ. of Tenn,  </textline>
<textline bbox="199.220,262.787,244.886,282.851" font="ArialMT" ncolour="1" size="20.064" colourspace="Pattern">USA  </textline>
<textline bbox="199.220,233.972,261.645,254.012" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">France </textline>
<textline bbox="199.220,205.172,235.873,225.212" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Italy </textline>
<textline bbox="199.220,176.372,281.685,196.412" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Germany </textline>
</textbox>
<textbox id="10" bbox="31.200,97.142,161.400,145.982" size="20.04">Rosenau 2001 
Angus 2000 <textline bbox="31.200,125.942,161.400,145.982" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Rosenau 2001 </textline>
<textline bbox="31.200,97.142,138.013,117.182" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Angus 2000 </textline>
</textbox>
<textbox id="11" bbox="199.220,75.544,329.661,145.982" size="20.04">Germany 
Australia-New  
Zealand <textline bbox="199.220,125.942,281.685,145.982" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Germany </textline>
<textline bbox="199.220,97.142,329.661,117.182" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Australia-New  </textline>
<textline bbox="199.220,75.544,271.625,95.584" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">Zealand </textline>
</textbox>
<textbox id="12" bbox="368.980,396.302,446.936,445.191" size="20.052"># of  
Patients <textline bbox="390.220,425.127,431.391,445.191" font="Arial-BoldMT" ncolour="1" size="20.064" colourspace="Pattern"># of  </textline>
<textline bbox="368.980,396.302,446.936,416.342" font="Arial-BoldMT" ncolour="1" size="20.040" colourspace="Pattern">Patients </textline>
</textbox>
<textbox id="13" bbox="396.820,334.792,419.122,383.632" size="20.04">24 
14 <textline bbox="396.820,363.592,419.122,383.632" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">24 </textline>
<textline bbox="396.820,334.792,419.122,354.832" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">14 </textline>
</textbox>
<textbox id="14" bbox="402.460,284.392,413.602,304.432" size="20.04">9 <textline bbox="402.460,284.392,413.602,304.432" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">9 </textline>
</textbox>
<textbox id="15" bbox="396.820,176.372,419.122,254.012" size="20.04">17 
26 
5 <textline bbox="396.820,233.972,419.122,254.012" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">17 </textline>
<textline bbox="396.820,205.172,419.122,225.212" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">26 </textline>
<textline bbox="402.460,176.372,413.602,196.412" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">5 </textline>
</textbox>
<textbox id="16" bbox="396.820,97.142,419.122,145.982" size="20.04">21 
37 <textline bbox="396.820,125.942,419.122,145.982" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">21 </textline>
<textline bbox="396.820,97.142,419.122,117.182" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">37 </textline>
</textbox>
<textbox id="17" bbox="487.270,284.392,613.101,383.632" size="20.04">60 months 
58.8 (15-107)  
months 
4.2 +/- 1.0 yr <textline bbox="487.270,363.592,580.696,383.632" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">60 months </textline>
<textline bbox="487.270,334.792,613.101,354.832" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">58.8 (15-107)  </textline>
<textline bbox="487.270,313.192,552.981,333.232" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">months </textline>
<textline bbox="487.270,284.392,599.730,304.432" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">4.2 +/- 1.0 yr </textline>
</textbox>
<textbox id="18" bbox="679.300,334.792,755.031,383.632" size="20.04">2 (8.3%) 
1 (7%)* <textline bbox="679.300,363.592,755.031,383.632" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">2 (8.3%) </textline>
<textline bbox="679.300,334.792,746.113,354.832" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">1 (7%)* </textline>
</textbox>
<textbox id="19" bbox="679.300,284.392,738.318,304.432" size="20.04">0 (0%) <textline bbox="679.300,284.392,738.318,304.432" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">0 (0%) </textline>
</textbox>
<textbox id="20" bbox="679.300,176.372,757.256,254.012" size="20.04">0 (0%) 
1 (4%) 
1 (20%)* <textline bbox="679.300,233.972,738.318,254.012" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">0 (0%) </textline>
<textline bbox="679.300,205.172,738.318,225.212" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">1 (4%) </textline>
<textline bbox="679.300,176.372,757.256,196.412" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">1 (20%)* </textline>
</textbox>
<textbox id="21" bbox="487.270,75.544,749.460,254.012" size="20.039999999999996">30 (12-48) months 
29 +/- 9 months 
26.6 (20-36)  
months 
643 (73-1473) days 4 (19%) 
18.4 +/- 12.1 (5-45)  
months <textline bbox="487.270,233.972,650.629,254.012" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">30 (12-48) months </textline>
<textline bbox="487.270,205.172,626.634,225.212" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">29 +/- 9 months </textline>
<textline bbox="487.270,176.372,601.959,196.412" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">26.6 (20-36)  </textline>
<textline bbox="487.270,154.742,552.981,174.782" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">months </textline>
<textline bbox="487.270,125.942,749.460,145.982" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">643 (73-1473) days 4 (19%) </textline>
<textline bbox="487.270,97.142,664.449,117.182" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">18.4 +/- 12.1 (5-45)  </textline>
<textline bbox="487.270,75.544,552.981,95.584" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">months </textline>
</textbox>
<textbox id="22" bbox="679.300,97.142,738.318,117.182" size="20.04">0 (0%) <textline bbox="679.300,97.142,738.318,117.182" font="ArialMT" ncolour="1" size="20.040" colourspace="Pattern">0 (0%) </textline>
</textbox>
<textbox id="23" bbox="31.200,28.980,472.056,46.980" size="18.0">*recurrence occurred after deviation from HBIg protocol <textline bbox="31.200,28.980,472.056,46.980" font="ArialMT" ncolour="1" size="18.000" colourspace="Pattern">*recurrence occurred after deviation from HBIg protocol </textline>
</textbox>
</page>
<page id="6" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="301.270,481.186,562.804,531.250" size="50.064">Alternatives <textline bbox="301.270,481.186,562.804,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">Alternatives </textline>
</textbox>
<textbox id="1" bbox="151.630,373.638,719.665,435.198" size="27.96">There are no good alternatives to HBIg for  
preventing recurrent HBV after OLT <textline bbox="151.630,407.238,719.665,435.198" font="Arial-BoldMT" ncolour="(1, 1, 0.8)" size="27.960" colourspace="Pattern">There are no good alternatives to HBIg for  </textline>
<textline bbox="196.390,373.638,667.404,401.598" font="Arial-BoldMT" ncolour="(1, 1, 0.8)" size="27.960" colourspace="Pattern">preventing recurrent HBV after OLT </textline>
</textbox>
<textbox id="2" bbox="238.780,321.132,626.080,353.172" size="32.04">Lamivudine Monotherapy <textline bbox="238.780,321.132,626.080,353.172" font="Arial-BoldMT" ncolour="(1, 1, 0.4)" size="32.040" colourspace="Pattern">Lamivudine Monotherapy </textline>
</textbox>
<textbox id="3" bbox="163.900,276.015,536.104,300.039" size="24.024">Not a viable solution for all patients <textline bbox="163.900,276.015,536.104,300.039" font="ArialMT" ncolour="1" size="24.024" colourspace="Pattern">Not a viable solution for all patients </textline>
</textbox>
<textbox id="4" bbox="163.900,189.600,655.180,236.640" size="24.0">Routine development of escape mutants/drug  
resistance <textline bbox="163.900,212.640,655.180,236.640" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">Routine development of escape mutants/drug  </textline>
<textline bbox="163.900,189.600,273.268,213.600" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">resistance </textline>
</textbox>
<textbox id="5" bbox="163.900,103.180,653.664,150.220" size="24.0">Historically 24-67% recurrence rate across all  
patients undergoing OLT for HBV <textline bbox="163.900,126.220,653.664,150.220" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">Historically 24-67% recurrence rate across all  </textline>
<textline bbox="163.900,103.180,516.460,127.180" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">patients undergoing OLT for HBV </textline>
</textbox>
<figure name="Image80" bbox="139.780,276.480,163.060,300.384" src="Image80.2x2.bmp" width="23" height="23">
</figure>
<figure name="Image82" bbox="139.780,213.120,163.060,237.000" src="Image82.2x2.bmp" width="23" height="23">
</figure>
<figure name="Image84" bbox="139.780,126.700,163.060,150.580" src="Image84.2x2.bmp" width="23" height="23">
</figure>
</page>
<page id="7" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="150.550,481.186,713.369,531.250" size="50.064">The UC Irvine Experience <textline bbox="150.550,481.186,713.369,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">The UC Irvine Experience </textline>
</textbox>
<textbox id="1" bbox="163.150,358.448,680.474,416.687" size="27.972">Patients with HBV-related end-stage liver  
failure, followed at our institution <textline bbox="163.150,388.703,680.474,416.687" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">Patients with HBV-related end-stage liver  </textline>
<textline bbox="163.150,358.448,563.509,386.408" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">failure, followed at our institution </textline>
</textbox>
<textbox id="2" bbox="163.150,247.548,673.550,305.787" size="27.972">Transplanted between 1993 and 2001 to  
ensure long-term follow up <textline bbox="163.150,277.803,673.550,305.787" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">Transplanted between 1993 and 2001 to  </textline>
<textline bbox="163.150,247.548,493.900,275.508" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">ensure long-term follow up </textline>
</textbox>
<textbox id="3" bbox="163.150,136.638,709.258,194.887" size="27.972">After OLT, all patients received combination  
therapy with HBIg and lamivudine <textline bbox="163.150,166.903,709.258,194.887" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">After OLT, all patients received combination  </textline>
<textline bbox="163.150,136.638,580.481,164.598" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">therapy with HBIg and lamivudine </textline>
</textbox>
<figure name="Image92" bbox="139.010,389.040,165.938,417.024" src="Image92.2x2.bmp" width="26" height="27">
</figure>
<figure name="Image94" bbox="139.010,278.160,165.938,306.144" src="Image94.2x2.bmp" width="26" height="27">
</figure>
<figure name="Image32" bbox="139.010,167.260,165.938,195.244" src="Image32.3.2x2.bmp" width="26" height="27">
</figure>
</page>
<page id="8" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="150.550,481.186,713.369,531.250" size="50.064">The UC Irvine Experience <textline bbox="150.550,481.186,713.369,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">The UC Irvine Experience </textline>
</textbox>
<textbox id="1" bbox="163.900,56.971,725.452,437.892" size="24.85661538461538">HBIg Protocol 
During the anhepatic phase, 10,000 IU of HBIg was  
given intravenously (IV) followed by 10,000 IU of  
HBIg IV daily for 6 days   
Administration of HBIg was then changed to the  
intramuscular (IM) route and the frequency of doses  
was adjusted to maintain HBsAb titers above  
150 IU/L  
Patients were evaluated on a monthly basis for the  
presence of HBV DNA and HBsAg until the HBsAb  
titers stabilized at therapeutic levels 
Thereafter, serology and HBsAb titers were checked  
every 2 months.  <textline bbox="315.720,402.852,549.016,437.892" font="Arial-BoldMT" ncolour="(1, 1, 0.4)" size="35.040" colourspace="Pattern">HBIg Protocol </textline>
<textline bbox="163.900,368.085,717.786,392.109" font="ArialMT" ncolour="1" size="24.024" colourspace="Pattern">During the anhepatic phase, 10,000 IU of HBIg was  </textline>
<textline bbox="163.900,342.140,685.940,366.140" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">given intravenously (IV) followed by 10,000 IU of  </textline>
<textline bbox="163.900,316.220,427.852,340.220" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">HBIg IV daily for 6 days   </textline>
<textline bbox="163.900,281.660,677.668,305.660" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">Administration of HBIg was then changed to the  </textline>
<textline bbox="163.900,255.735,721.401,279.759" font="ArialMT" ncolour="1" size="24.024" colourspace="Pattern">intramuscular (IM) route and the frequency of doses  </textline>
<textline bbox="163.900,229.800,646.756,253.800" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">was adjusted to maintain HBsAb titers above  </textline>
<textline bbox="163.900,203.880,260.572,227.880" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">150 IU/L  </textline>
<textline bbox="163.900,169.315,708.356,193.339" font="ArialMT" ncolour="1" size="24.024" colourspace="Pattern">Patients were evaluated on a monthly basis for the  </textline>
<textline bbox="163.900,143.380,708.052,167.380" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">presence of HBV DNA and HBsAg until the HBsAb  </textline>
<textline bbox="163.900,117.460,542.740,141.460" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">titers stabilized at therapeutic levels </textline>
<textline bbox="163.900,82.896,725.452,106.896" font="ArialMT" ncolour="1" size="24.000" colourspace="Pattern">Thereafter, serology and HBsAb titers were checked  </textline>
<textline bbox="163.900,56.971,341.293,80.995" font="ArialMT" ncolour="1" size="24.024" colourspace="Pattern">every 2 months.  </textline>
</textbox>
<figure name="Image100" bbox="139.780,368.570,163.060,392.474" src="Image100.2x2.bmp" width="23" height="23">
</figure>
<figure name="Image100" bbox="139.780,282.140,163.060,306.020" src="Image100.0.2x2.bmp" width="23" height="23">
</figure>
<figure name="Image84" bbox="139.780,169.800,163.060,193.704" src="Image84.0.2x2.bmp" width="23" height="23">
</figure>
<figure name="Image100" bbox="139.780,83.376,163.060,107.256" src="Image100.1.2x2.bmp" width="23" height="23">
</figure>
</page>
<page id="9" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="150.550,481.186,713.369,531.250" size="50.064">The UC Irvine Experience <textline bbox="150.550,481.186,713.369,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">The UC Irvine Experience </textline>
</textbox>
<textbox id="1" bbox="235.220,155.000,422.696,281.030" size="18.004">Kaplan-Meier Survival 
95.0% at 1-month 
85.0% at 1-year 
79.7% at 3-years 
73.1% at 5-years 
66.4% at 10-years <textline bbox="235.220,263.030,422.696,281.030" font="Arial-BoldMT" ncolour="(0.2, 0.396, 0.984)" size="18.000" colourspace="Pattern">Kaplan-Meier Survival </textline>
<textline bbox="260.180,241.430,402.182,259.430" font="ArialMT" ncolour="(0.2, 0.396, 0.984)" size="18.000" colourspace="Pattern">95.0% at 1-month </textline>
<textline bbox="260.180,219.825,386.946,237.849" font="ArialMT" ncolour="(0.2, 0.396, 0.984)" size="18.024" colourspace="Pattern">85.0% at 1-year </textline>
<textline bbox="260.180,198.200,395.936,216.200" font="ArialMT" ncolour="(0.2, 0.396, 0.984)" size="18.000" colourspace="Pattern">79.7% at 3-years </textline>
<textline bbox="260.180,176.600,395.936,194.600" font="ArialMT" ncolour="(0.2, 0.396, 0.984)" size="18.000" colourspace="Pattern">73.1% at 5-years </textline>
<textline bbox="260.180,155.000,405.896,173.000" font="ArialMT" ncolour="(0.2, 0.396, 0.984)" size="18.000" colourspace="Pattern">66.4% at 10-years </textline>
</textbox>
<textbox id="2" bbox="250.220,133.400,471.662,151.400" size="18.0">mean 87.8 month follow-up  <textline bbox="250.220,133.400,471.662,151.400" font="ArialMT" ncolour="(0.2, 0.396, 0.984)" size="18.000" colourspace="Pattern">mean 87.8 month follow-up  </textline>
</textbox>
<figure name="Image106" bbox="114.000,32.400,750.000,466.920" src="Image106.jpg" width="636" height="434">
</figure>
</page>
<page id="10" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="150.550,481.186,713.369,531.250" size="50.064">The UC Irvine Experience <textline bbox="150.550,481.186,713.369,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">The UC Irvine Experience </textline>
</textbox>
<textbox id="1" bbox="331.300,398.890,549.640,428.890" size="30.0">Overall Results <textline bbox="331.300,398.890,549.640,428.890" font="Arial-BoldMT" ncolour="(1, 1, 0.4)" size="30.000" colourspace="Pattern">Overall Results </textline>
</textbox>
<textbox id="2" bbox="70.728,322.433,156.246,368.158" size="21.972"># of  
Patients <textline bbox="93.888,346.198,139.082,368.158" font="Arial-BoldMT" ncolour="1" size="21.960" colourspace="Pattern"># of  </textline>
<textline bbox="70.728,322.433,156.246,344.417" font="Arial-BoldMT" ncolour="1" size="21.984" colourspace="Pattern">Patients </textline>
</textbox>
<textbox id="3" bbox="197.420,298.648,287.610,368.158" size="21.968"># DNA +  
prior to  
OLT <textline bbox="197.420,346.198,287.610,368.158" font="Arial-BoldMT" ncolour="1" size="21.960" colourspace="Pattern"># DNA +  </textline>
<textline bbox="201.020,322.433,284.142,344.417" font="Arial-BoldMT" ncolour="1" size="21.984" colourspace="Pattern">prior to  </textline>
<textline bbox="218.420,298.648,260.627,320.608" font="Arial-BoldMT" ncolour="1" size="21.960" colourspace="Pattern">OLT </textline>
</textbox>
<textbox id="4" bbox="325.150,322.433,439.913,368.158" size="21.972">Continued  
HBIg <textline bbox="325.150,346.198,439.913,368.158" font="Arial-BoldMT" ncolour="1" size="21.960" colourspace="Pattern">Continued  </textline>
<textline bbox="353.860,322.433,405.149,344.417" font="Arial-BoldMT" ncolour="1" size="21.984" colourspace="Pattern">HBIg </textline>
</textbox>
<textbox id="5" bbox="471.100,322.433,580.966,368.158" size="21.972">Recurrent  
HBV <textline bbox="471.100,346.198,580.966,368.158" font="Arial-BoldMT" ncolour="1" size="21.960" colourspace="Pattern">Recurrent  </textline>
<textline bbox="499.900,322.433,546.291,344.417" font="Arial-BoldMT" ncolour="1" size="21.984" colourspace="Pattern">HBV </textline>
</textbox>
<textbox id="6" bbox="649.540,322.433,759.685,368.158" size="21.972">Follow-up  
months <textline bbox="649.540,346.198,759.685,368.158" font="Arial-BoldMT" ncolour="1" size="21.960" colourspace="Pattern">Follow-up  </textline>
<textline bbox="661.900,322.433,741.284,344.417" font="Arial-BoldMT" ncolour="1" size="21.984" colourspace="Pattern">months </textline>
</textbox>
<textbox id="7" bbox="101.210,245.368,125.660,267.328" size="21.96">10 <textline bbox="101.210,245.368,125.660,267.328" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">10 </textline>
</textbox>
<textbox id="8" bbox="107.330,168.308,119.540,190.268" size="21.96">6 <textline bbox="107.330,168.308,119.540,190.268" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">6 </textline>
</textbox>
<textbox id="9" bbox="233.420,245.368,245.630,267.328" size="21.96">2 <textline bbox="233.420,245.368,245.630,267.328" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">2 </textline>
</textbox>
<textbox id="10" bbox="233.420,168.308,245.630,190.268" size="21.96">0 <textline bbox="233.420,168.308,245.630,190.268" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">0 </textline>
</textbox>
<textbox id="11" bbox="361.540,245.368,397.335,267.328" size="21.96">Yes <textline bbox="361.540,245.368,397.335,267.328" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">Yes </textline>
</textbox>
<textbox id="12" bbox="490.660,245.368,555.398,267.328" size="21.96">0 (0%) <textline bbox="490.660,245.368,555.398,267.328" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">0 (0%) </textline>
</textbox>
<textbox id="13" bbox="365.500,168.308,393.550,190.268" size="21.96">No <textline bbox="365.500,168.308,393.550,190.268" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">No </textline>
</textbox>
<textbox id="14" bbox="484.540,168.308,561.532,190.268" size="21.96">3 (50%) <textline bbox="484.540,168.308,561.532,190.268" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">3 (50%) </textline>
</textbox>
<textbox id="15" bbox="629.590,213.683,779.691,267.328" size="21.972">80.2  
(range 34-115)  <textline bbox="680.140,245.368,729.023,267.328" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">80.2  </textline>
<textline bbox="629.590,213.683,779.691,235.667" font="ArialMT" ncolour="1" size="21.984" colourspace="Pattern">(range 34-115)  </textline>
</textbox>
<textbox id="16" bbox="610.390,136.628,798.847,190.268" size="21.96">100.6 
(range 36.3-148.7)  <textline bbox="674.020,168.308,729.030,190.268" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">100.6 </textline>
<textline bbox="610.390,136.628,798.847,158.588" font="ArialMT" ncolour="1" size="21.960" colourspace="Pattern">(range 36.3-148.7)  </textline>
</textbox>
</page>
<page id="11" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="150.550,481.186,713.369,531.250" size="50.064">The UC Irvine Experience <textline bbox="150.550,481.186,713.369,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">The UC Irvine Experience </textline>
</textbox>
<textbox id="1" bbox="163.150,328.208,702.318,416.687" size="27.968">3 patients experienced recurrent HBV after  
cessation of HBIg and institution of  
lamivudine monotherapy <textline bbox="163.150,388.703,702.318,416.687" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">3 patients experienced recurrent HBV after  </textline>
<textline bbox="163.150,358.448,602.178,386.408" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">cessation of HBIg and institution of  </textline>
<textline bbox="163.150,328.208,468.473,356.168" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">lamivudine monotherapy </textline>
</textbox>
<textbox id="2" bbox="163.150,187.068,691.203,275.508" size="27.959999999999997">Retrospectively, laboratory data  
demonstrates a marked increase in viral  
replication as HBsAb titers were depleted   <textline bbox="163.150,247.548,562.950,275.508" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">Retrospectively, laboratory data  </textline>
<textline bbox="163.150,217.308,667.940,245.268" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">demonstrates a marked increase in viral  </textline>
<textline bbox="163.150,187.068,691.203,215.028" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">replication as HBsAb titers were depleted   </textline>
</textbox>
<figure name="Image32" bbox="139.010,389.040,165.938,417.024" src="Image32.4.2x2.bmp" width="26" height="27">
</figure>
<figure name="Image32" bbox="139.010,247.900,165.938,275.860" src="Image32.5.2x2.bmp" width="26" height="27">
</figure>
</page>
<page id="12" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="302.590,481.186,561.421,531.250" size="50.064">Conclusions <textline bbox="302.590,481.186,561.421,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">Conclusions </textline>
</textbox>
<textbox id="1" bbox="163.150,297.968,714.549,416.687" size="27.966">Published data strongly supports the use of  
combination therapy with HBIg and a  
nucleoside analog to prevent recurrent HBV  
after OLT <textline bbox="163.150,388.703,708.474,416.687" font="ArialMT" ncolour="1" size="27.984" colourspace="Pattern">Published data strongly supports the use of  </textline>
<textline bbox="163.150,358.448,628.936,386.408" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">combination therapy with HBIg and a  </textline>
<textline bbox="163.150,328.208,714.549,356.168" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">nucleoside analog to prevent recurrent HBV  </textline>
<textline bbox="163.150,297.968,279.324,325.928" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">after OLT </textline>
</textbox>
<textbox id="2" bbox="163.150,217.308,698.975,245.268" size="27.96">There are no viable alternatives at this time <textline bbox="163.150,217.308,698.975,245.268" font="ArialMT" ncolour="1" size="27.960" colourspace="Pattern">There are no viable alternatives at this time </textline>
</textbox>
<figure name="Image32" bbox="139.010,389.040,165.938,417.024" src="Image32.6.2x2.bmp" width="26" height="27">
</figure>
<figure name="Image32" bbox="139.010,217.660,165.938,245.620" src="Image32.7.2x2.bmp" width="26" height="27">
</figure>
</page>
<page id="13" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="315.820,481.186,548.267,531.250" size="50.064">References <textline bbox="315.820,481.186,548.267,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">References </textline>
</textbox>
<textbox id="1" bbox="61.872,44.240,830.466,476.938" size="15.963999999999997">Anselmo DM, Ghobrial RM, Busuttil RW., et al. New era of liver transplantation for hepatitis B: a 17-year  
single-center experience. Ann Surg. 2002 May;235(5):611-9; discussion 619-20. 
Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus- 
related liver disease. Hepatology 1991;13:619-626. 
O&#8217;Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation.  
Serological and clinical implications. J Hepatology 1992;14:104-111. 
Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology 1990;12:364-366. 
Perillo RP, Mason AL. Hepatitis B and liver transplantation. Problems and promises. N Engl J Med  
1993;329:1885-1887. 
Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transplantation 2002;8:S67-73. 
Roche B, Feray C, Samuel D, et al. HBV DNA persistence 10 years after liver transplantation despite  
successful anti-HBS passive Immunoprophylaxis. Hepatology 2003;38:86-95. 
Chu CJ, Fontana RJ, Moore C, et al. Outcome of liver transplantation for hepatitis B: report of a single  
center's experience. 
Liver Transpl. 2001 Aug;7(8):724-31. 
Han SH, Ofman J, Martin P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B  
immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation  
compared with hepatitis B immune globulin monotherapy. Liver Transplantation 2000;6:741-748. 
Honaker MR, Shokouh-Amiri MH, Vera SR, et al. Evolving experience of hepatitis B virus prophylaxis in liver  
transplantation. Transpl Infect Dis. 2002 Sep;4(3):137-43. 
Perillo RP, Wright T, Rakela J, Levy G, et al. A multicenter United States-Canadian trial to assess lamivudine  
monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-432.  
Mutimer D, Dusheiko G, Barrett C, Grellier et al. Lamivudine without HBIg for prevention of graft reinfection  
by hepatitis B: long-term follow-up. Transplantation 2000;70:809-15. <textline bbox="61.872,460.978,799.874,476.938" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Anselmo DM, Ghobrial RM, Busuttil RW., et al. New era of liver transplantation for hepatitis B: a 17-year  </textline>
<textline bbox="61.872,445.618,627.137,461.578" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">single-center experience. Ann Surg. 2002 May;235(5):611-9; discussion 619-20. </textline>
<textline bbox="61.872,424.498,802.525,440.458" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus- </textline>
<textline bbox="61.872,409.138,423.477,425.098" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">related liver disease. Hepatology 1991;13:619-626. </textline>
<textline bbox="61.872,388.018,814.455,403.978" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">O&#8217;Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation.  </textline>
<textline bbox="61.872,372.653,541.575,388.637" font="ArialMT" ncolour="1" size="15.984" colourspace="Pattern">Serological and clinical implications. J Hepatology 1992;14:104-111. </textline>
<textline bbox="61.872,351.508,764.327,367.468" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology 1990;12:364-366. </textline>
<textline bbox="61.872,330.388,757.393,346.348" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Perillo RP, Mason AL. Hepatitis B and liver transplantation. Problems and promises. N Engl J Med  </textline>
<textline bbox="61.872,315.028,213.697,330.988" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">1993;329:1885-1887. </textline>
<textline bbox="61.872,293.908,813.407,309.868" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transplantation 2002;8:S67-73. </textline>
<textline bbox="61.872,272.788,778.610,288.748" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Roche B, Feray C, Samuel D, et al. HBV DNA persistence 10 years after liver transplantation despite  </textline>
<textline bbox="61.872,257.423,608.304,273.407" font="ArialMT" ncolour="1" size="15.984" colourspace="Pattern">successful anti-HBS passive Immunoprophylaxis. Hepatology 2003;38:86-95. </textline>
<textline bbox="61.872,236.288,786.264,252.248" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Chu CJ, Fontana RJ, Moore C, et al. Outcome of liver transplantation for hepatitis B: report of a single  </textline>
<textline bbox="61.872,220.928,204.379,236.888" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">center's experience. </textline>
<textline bbox="61.872,205.568,321.237,221.528" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Liver Transpl. 2001 Aug;7(8):724-31. </textline>
<textline bbox="61.872,184.448,796.786,200.408" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Han SH, Ofman J, Martin P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B  </textline>
<textline bbox="61.872,169.088,772.012,185.048" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation  </textline>
<textline bbox="61.872,153.723,740.694,169.707" font="ArialMT" ncolour="1" size="15.984" colourspace="Pattern">compared with hepatitis B immune globulin monotherapy. Liver Transplantation 2000;6:741-748. </textline>
<textline bbox="61.872,132.588,829.842,148.548" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Honaker MR, Shokouh-Amiri MH, Vera SR, et al. Evolving experience of hepatitis B virus prophylaxis in liver  </textline>
<textline bbox="61.872,117.228,468.117,133.188" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">transplantation. Transpl Infect Dis. 2002 Sep;4(3):137-43. </textline>
<textline bbox="61.872,96.104,830.466,112.064" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Perillo RP, Wright T, Rakela J, Levy G, et al. A multicenter United States-Canadian trial to assess lamivudine  </textline>
<textline bbox="61.872,80.744,798.290,96.704" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-432.  </textline>
<textline bbox="61.872,59.619,821.623,75.603" font="ArialMT" ncolour="1" size="15.984" colourspace="Pattern">Mutimer D, Dusheiko G, Barrett C, Grellier et al. Lamivudine without HBIg for prevention of graft reinfection  </textline>
<textline bbox="61.872,44.240,541.937,60.200" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">by hepatitis B: long-term follow-up. Transplantation 2000;70:809-15. </textline>
</textbox>
</page>
<page id="14" bbox="0.000,0.000,864.000,576.000" rotate="0">
<textbox id="0" bbox="315.820,481.186,548.267,531.250" size="50.064">References <textline bbox="315.820,481.186,548.267,531.250" font="TimesNewRomanPS-BoldMT" ncolour="(0.98, 0.992, 0)" size="50.064" colourspace="Pattern">References </textline>
</textbox>
<textbox id="1" bbox="61.992,76.904,860.121,476.938" size="15.963130434782606">Malkan G, Cattral MS, Humar A, et al. Lamivudine for hepatitis B in liver transplantation: a single-center  
experience. Transplantation 2000;69:1403-7. 
Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of  
lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatology 1999;30:715-721. 
Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver  
transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001  
Jun;34(6):903-10. 
Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine  
therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000 Jul;6(4):429- 
33. 
Neff GW, O&#8217;Brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and  
recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004;10:1372-1378. 
Albeniz Arbizu E, Barcena Marugan R, Oton Nieto E, et al. Use of combined treatment of hepatitis B immune  
globulin and lamivudine as prevention of hepatitis B virus recurrence in liver allograft. Transplant Proc. 2003  
Aug;35(5):1844-5.  
Engler S, Sauer P, Klar E, et al. Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudin  
and hepatitis B immunoglobulin. Transplant Proc. 2002 Sep;34(6):2285-7. 
Dumortier J, Chevallier P, Scoazec JY, et al. Combined lamivudine and hepatitis B immunoglobulin for the  
prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant. 2003  
Aug;3(8):999-1002. 
Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of  
hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to  
transplantation as a risk factor for reinfection. J Hepatol. 2001 Jun;34(6):895-902. <textline bbox="61.992,460.978,797.088,476.938" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Malkan G, Cattral MS, Humar A, et al. Lamivudine for hepatitis B in liver transplantation: a single-center  </textline>
<textline bbox="61.992,445.618,379.197,461.578" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">experience. Transplantation 2000;69:1403-7. </textline>
<textline bbox="61.992,424.498,785.311,440.458" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of  </textline>
<textline bbox="61.992,409.138,786.647,425.098" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatology 1999;30:715-721. </textline>
<textline bbox="61.992,388.018,802.163,403.978" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver  </textline>
<textline bbox="61.992,372.653,831.078,388.637" font="ArialMT" ncolour="1" size="15.984" colourspace="Pattern">transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001  </textline>
<textline bbox="61.992,357.268,188.017,373.228" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Jun;34(6):903-10. </textline>
<textline bbox="61.992,336.148,856.828,352.108" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine  </textline>
<textline bbox="61.992,320.788,843.345,336.748" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000 Jul;6(4):429- </textline>
<textline bbox="61.992,305.428,84.237,321.388" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">33. </textline>
<textline bbox="61.992,284.308,853.298,300.268" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Neff GW, O&#8217;Brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and  </textline>
<textline bbox="61.992,268.943,811.254,284.927" font="ArialMT" ncolour="1" size="15.984" colourspace="Pattern">recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004;10:1372-1378. </textline>
<textline bbox="61.992,247.808,835.031,263.768" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Albeniz Arbizu E, Barcena Marugan R, Oton Nieto E, et al. Use of combined treatment of hepatitis B immune  </textline>
<textline bbox="61.992,232.448,828.295,248.408" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">globulin and lamivudine as prevention of hepatitis B virus recurrence in liver allograft. Transplant Proc. 2003  </textline>
<textline bbox="61.992,217.088,195.100,233.048" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Aug;35(5):1844-5.  </textline>
<textline bbox="61.992,195.968,839.100,211.928" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Engler S, Sauer P, Klar E, et al. Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudin  </textline>
<textline bbox="61.992,180.608,582.737,196.568" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">and hepatitis B immunoglobulin. Transplant Proc. 2002 Sep;34(6):2285-7. </textline>
<textline bbox="61.992,159.483,811.533,175.467" font="ArialMT" ncolour="1" size="15.984" colourspace="Pattern">Dumortier J, Chevallier P, Scoazec JY, et al. Combined lamivudine and hepatitis B immunoglobulin for the  </textline>
<textline bbox="61.992,144.108,795.226,160.068" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant. 2003  </textline>
<textline bbox="61.992,128.748,199.537,144.708" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Aug;3(8):999-1002. </textline>
<textline bbox="61.992,107.628,860.121,123.588" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of  </textline>
<textline bbox="61.992,92.264,773.888,108.224" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to  </textline>
<textline bbox="61.992,76.904,637.649,92.864" font="ArialMT" ncolour="1" size="15.960" colourspace="Pattern">transplantation as a risk factor for reinfection. J Hepatol. 2001 Jun;34(6):895-902. </textline>
</textbox>
</page>
</pages>